Assessment of vascular dysfunction in patients without obstructive coronary artery disease: why, how and when by Ford, Tom J. et al.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 1 3 , N O . 1 6 , 2 0 2 0
ª 2 0 2 0 T H E A U T H O R S . P U B L I S H E D B Y E L S E V I E R O N B E H A L F O F T H E A M E R I C A N
C O L L E G E O F C A R D I O L O G Y F OU N D A T I O N . T H I S I S A N O P E N A C C E S S A R T I C L E U N D E R
T H E C C B Y L I C E N S E ( h t t p : / / c r e a t i v e c o mm o n s . o r g / l i c e n s e s / b y / 4 . 0 / ) .STATE-OF-THE-ART REVIEWAssessment of Vascular Dysfunction
in Patients Without Obstructive
Coronary Artery Disease
Why, How, and WhenThomas J. Ford, MD, PHD,a,b,c Peter Ong, MD, PHD,d Udo Sechtem, MD,d John Beltrame, MD, PHD,e
Paolo G. Camici, MD,f Filippo Crea, MD, PHD,g Juan-Carlos Kaski, MD, DSC,h C. Noel Bairey Merz, MD,i
Carl J. Pepine, MD, PHD,j Hiroaki Shimokawa, MD, PHD,k Colin Berry, MD, PHD,a,l
on behalf of the COVADIS Study GroupABSTRACTISS
Fro
bFa
Lo
He
Sa
Un
Lo
Lo
dio
Ju
(N
HL
De
He
26
Ve
ceu
un
anIschemic heart disease secondary to coronary vascular dysfunction causes angina and impairs quality of life and
prognosis. About one-half of patients with symptoms and signs of ischemia turn out not to have obstructive coronary
artery disease, and coronary vascular dysfunction may be relevant. Adjunctive tests of coronary vasomotion include
guidewire-based techniques with adenosine and reactivity testing, typically by intracoronary infusion of acetylcholine.
The CorMicA (Coronary Microvascular Angina) trial provided evidence that routine management guided by an inter-
ventional diagnostic procedure and stratified therapy improves angina and quality of life in patients with angina but no
obstructive coronary artery disease. In this paper, the COVADIS study group provide a comprehensive review of why,
how, and when coronary vascular dysfunction should be assessed invasively. They discuss the rationale through a
shared understanding of vascular pathophysiology and clinical evidence. They propose a consensus approach to how an
interventional diagnostic procedure is performed with focus on practical aspects. Finally, the authors discuss the
clinical scenarios in patients with stable and acute coronary syndromes in which measurement of coronary vascular
function may be helpful for patient care. (J Am Coll Cardiol Intv 2020;13:1847–64) © 2020 The Authors. Published by
Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).N 1936-8798 https://doi.org/10.1016/j.jcin.2020.05.052
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ABBR EV I A T I ON S
AND ACRONYMS
CAD = coronary artery disease
CBF = coronary blood flow
CFR = coronary flow reserve
CI = confidence interval
CTCA = computed
tomographic coronary
angiography
FFR = fractional flow reserve
IDP = interventional diagnostic
procedure
IMR = index of microvascular
resistance
INOCA = ischemia with no
obstructive coronary artery
disease
LV = left ventricular
LVEDP = left ventricular end-
diastolic pressure
MACE = major adverse
cardiovascular event(s)
MB = myocardial bridge
MI = myocardial infarction
MVA = microvascular angina
VSA = vasospastic angina
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1848HIGHLIGHTS
 Patients with symptoms of INOCA can
have treatable coronary vasomotion
disorders.
 Epicardial and microvascular vasospasm
may cause MI with no obstructive CAD
and type 2 MI.
 Invasive physiological testing (functional
coronary angiography) helps exclude,
diagnose, and treat these conditions.
 Stratified medicine can transform the
management and well-being of these
patients.I schemic heart disease is a leading globalcause of premature disability (1) anddeath (2). The classic cause of ischemic
heart disease is coronary atherosclerosis,
but disorders of coronary vasomotion are
increasingly recognized (3–5). Approximately
one-half of patients undergoing coronary
angiography for known or suspected angina
are found to have nonobstructed epicardial
coronary arteries, and vasomotion disorders,
including microvascular angina (MVA)
and/or vasospastic angina (VSA), may be
relevant. Coronary angiography has very
limited sensitivity for the detection of these
disorders (Figure 1).
Epicardial artery spasm causes VSA, first
described by Prinzmetal et al. (6) as “variant
angina.” Microvascular spasm and/or
impaired coronary vasodilation cause MVA,
formerly known as cardiac syndrome X (5).
Vasospastic disorders of the conduit arteries
and microvessels are diagnosed using
acetylcholine reactivity testing and often
coexist with coronary atherosclerosis. More-
over, coronary vascular dysfunction,
whether epicardial or microvascular, can alsocause myocardial ischemia in patients with obstruc-
tive coronary artery disease (CAD) (3–5).
Coronary vasomotion disorders cause a relative
supply-demand mismatch of myocardial blood flow
and nutrients relative to their requirements, inducing
myocardial ischemia that may be transient, recurrent,
and/or chronic. Ischemia with no obstructive CAD
(INOCA) is typically a chronic health problem (7,8).1, R01 HL090957, and 1R03AG032631), the National Center for Re
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FIGURE 1 Clinical Utility of an IDP in Patients With Symptoms and/or Signs of Ischemia But No Obstructive CAD
Invasive Coronary Assessment in INOCA
Two patients with similar baseline angiograms and clinical presentations without obstructive epicardial coronary artery disease (CAD). Each patient undergoes the an
interventional diagnostic procedure (IDP), which reveals a distinct diagnosis. Therapies for microvascular and vasospastic angina are distinct and should be guided by
the IDP results. The yellow figure shows a typical case of vasospastic angina with preserved microvascular function. The patient was previously on a beta-blocker, and
this was substituted for by a calcium-channel blocker with smoking cessation counseling. The blue figure depicts a patient with proven microvascular dysfunction but
no severe vasospasm. There were abnormalities in both microcirculatory resistance (index of microcirculatory resistance [IMR]) and coronary vasodilator reserve
(coronary flow reserve [CFR]). The patient had a diagnosis of microvascular angina and cessation of long-acting nitrate medication with up-titration of a beta-blocker.
The patient underwent cardiac rehabilitation classes to assist in weight loss and identify relevant life-style factors implicated in the condition. Note that some operators
may prefer to perform vasoreactivity testing before instrumenting the artery for guidewire based invasive CFR and microvascular resistance measurement.
ACEi ¼ angiotensin-converting enzyme inhibitor; angio ¼ angiography; DS ¼ diameter stenosis; ECG ¼ electrocardiography; FFR ¼ fractional flow reserve;
GTN ¼ glyceryl trinitrate; rehab ¼ rehabilitation.
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1849obstructive lesion, so in this review we focus on pa-
tients without epicardial obstruction.
In this review, we describe why, how, and when
coronary vascular function should be measured in
selected patients in the cardiac catheterization labo-
ratory. Interventional cardiologists work at the crit-
ical point in the care pathway for diagnosis of and
therapy for patients with INOCA, so interventional
cardiologists are the target audience for this review.
We outline the rationale for why invasive measure-
ments of coronary function are clinically relevant, in
line with emerging results from recent trials. We
describe how coronary vasomotion assessment with
an “interventional diagnostic procedure” (IDP) isperformed, with a focus on practical considerations
and tips and tricks in the catheterization laboratory.
We then describe the clinical indications for when an
adjunctive IDP should be performed in daily practice.
Finally, we consider future directions.
WHY MEASURE CORONARY
VASCULAR FUNCTION?
The rationale for adjunctive testing of coronary
vascular function during invasive angiography is 3-
fold: diagnosis, prognosis, and treatment implica-
tions. First, a normal angiographic study does not
exclude a disorder of coronary vascular function. In a
CENTRAL ILLUSTRATION Limited Visualization of the Coronary Microvasculature With
Invasive Coronary Angiography
Ford, T.J. et al. J Am Coll Cardiol Intv. 2020;13(16):1847–64.
Continued on the next page
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TABLE 1 Proposed Standardized Diagnostic Criteria: Coronary Vascular Dysfunction
Diagnostic Group Outcome Definitions: Disorders of Coronary Artery Function
Microvascular angina  Abnormal microvascular resistance
 Impaired coronary vasorelaxation
 Microvascular spasm
IMR $25
HMR >2.4
CFR by thermodilution <2.0
Angina during intracoronary infusion of acetylcholine with typical ischemic ST-
segment changes without epicardial coronary constriction (<90% reduction) in
coronary artery diameter*
Vasospastic angina Epicardial spasm Reduction in coronary diameter >90% following intracoronary acetylcholine from
baseline in any epicardial coronary artery segment together with symptoms and
ST-segment deviation on ECG†
Obstructive epicardial coronary
disease
FFR #0.80
Contrast FFR #0.83
Resting indices (i.e., iFR, NHPR) #0.89
Endothelial dysfunction Impaired vasodilatation and/or impaired increase in coronary flow velocity in
response to intracoronary infusion of low doses (1–30 mg) of acetylcholine
*Microvascular spasm may occur earlier than diffuse, distal spasm of a conduit artery. †Prinzmetal vasospasm is typically focal.
CFR ¼ coronary flow reserve; ECG ¼ electrocardiography; FFR ¼ fractional flow reserve; HMR ¼ hyperemic microvascular resistance; iFR ¼ instantaneous wave-free ratio; IMR ¼ index of microcirculatory
resistance; NHPR ¼ nonhyperemic pressure ratio.
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1851symptomatic patient with INOCA, coronary angiog-
raphy may be considered incomplete without adjunc-
tive diagnostic tests of coronary vascular dysfunction
(Central Illustration, Table 1) (9,23,24). Other methods,
such as intravascular imaging, are informative for
myocardial bridging but not for vascular dysfunction.
Second, in an undifferentiated population of pa-
tients undergoing invasive management during daily
practice, an IDP empowers cardiologists to make the
correct diagnosis with linked therapy (Figure 1). Strat-
ified medicine is the identification of key subgroups of
patients (endotypes) within an undifferentiated, het-
erogeneous population, these endotypes (MVA, VSA,
both, or none) being distinguishable by distinct
mechanisms of disease and/or responses to linked
therapy (Figure 1) (25). The tests empower clinicians to
include or exclude coronary vascular dysfunction in
affected patients, and discrimination of angina due to
vasospasm and/or impaired vasodilator reserve
(functional disorder) from increased microvascular
resistance (structural disorder) permits specific and
distinct treatments outlined in practice guidelines (9).
Third, demonstration of coronary vascular
dysfunction as a mechanism or cause of myocardialCENTRAL ILLUSTRATION Continued
(A) This figure illustrates a typical normal coronary angiogram (left) wi
artery. The right image is a bismuth stereo angiogram from a cadaveric h
Fulton (reproduced with permission from Fulton [30]). This image offer
trasting starkly with the lack of microcirculatory information on the inv
compartmentalized physiological assessment according to the probes ac
nonhyperemic pressure ratios are predominantly tests of epicardial coro
resistance and hyperemic microcirculatory resistance are more specific t
metric that can be influenced by any combination of epicardial or microischemia provides new prognostic information
empowering patients and clinicians to adopt optimal
guideline-directed preventive therapy and enhancing
treatment satisfaction (14,16).
DIAGNOSIS. Coronary angiography is the standard-
of-care test for identifying obstructive CAD either by
anatomic imaging using noninvasive computed
tomographic coronary angiography (CTCA) or inva-
sive coronary angiography (26,27). Although proced-
ure numbers worldwide are uncertain, approximately
10 million invasive coronary angiographic examina-
tions are performed annually, including 4 million per
year in Europe and the United States (28,29). Invasive
coronary angiography has a spatial resolution of
approximately 0.5 mm, and evaluation is determined
by subjective visual interpretation. The limited
spatial resolution of angiography does not allow
visualization of the resistance arterioles (20 to
400 mm) that largely govern myocardial blood flow
(Figure 1) (30).
The noninvasive management of symptomatic pa-
tients has evolved in recent years. In Europe, practice
guidelines for the management of symptomaticth a smooth and well-opacified left anterior descending coronary
eart in work performed more than 50 years ago by the late Prof. S.
s an unsurpassed illustration of the coronary microcirculation, con-
asive coronary angiogram (30). (B) This schematic illustrates
etylcholine and adenosine. The metrics fractional flow reserve and
nary obstruction to blood flow, whereas index of microcirculatory
o the microcirculatory function. Finally, coronary flow reserve is a
vascular disease or changes in resting flow.
TABLE 2 Practical Considerations for Invasive Assessment of Coronary Vascular Function
Procedure Practical Points
Set-up Acetylcholine may be pre-ordered, according to local arrangements.
Obtain informed consent.
Undertake team briefing on indication and protocol.
Administer heparin 5,000 IU (as per local standard care procedures).
Use radial artery access; avoid administration of vasodilator drugs, as they may confound measurement of coronary vascular function.
Administer short-acting intra-arterial GTN (avoid verapamil/GDN).
Use a 5-F guide catheter to reduce spasm in small radial arteries.
Coronary angiography
Projection Choose an imaging projection that reveals the long axis of the target vessel (i.e., no foreshortening), with minimal vessel overlap.
TIMI frame count Ensure that cine acquisition is sufficiently long to assess for myocardial blush of contrast media.
Diagnostic guidewire A single target coronary artery may be sufficient for diagnosis and decision making; in general, select the left anterior descending coronary
artery.
If normal results are obtained and clinical suspicion remains high, consider undertaking the IDP in a second coronary artery.
Advance the guidewire into the distal third of the target coronary artery.
ComboWire Doppler Consider using a buddy wire to safely advance the ComboWire.
Coronary reactivity testing Avoid a vasodilator cocktail in radial procedures.
Retain the buddy wire in situ to facilitate direct intracoronary testing.
A dedicated intracoronary catheter is generally not necessary (and may increase the risks of the procedure); injection of acetylcholine is done
through the guiding catheter into the lumen of the left main coronary artery. Prior to starting the infusion of acetylcholine, initially flush the
lumen of the guide withw2 ml of the infusate (depending on the French size of the catheter used) to replace the flushing saline in the shaft
of the catheter. Once the acetylcholine solution has reached the tip of the catheter, further injection is done more slowly and steadily over
20 s. The catheter is then slowly refilled with saline, remembering that this procedure will lead to extrusion of acetylcholine at the tip of the
catheter for at least as long until all the acetylcholine solution is replaced by saline.
If infusing into a “dominant” coronary artery, consider “half dose” of the acetylcholine to limit bradycardia.
In cases with normal coronary function or “negative” test responses, if clinical suspicion persists, a dose of 200 mg may be infused into the left
coronary artery, increasing sensitivity without impairment of specificity.
Use isosorbide dinitrate, which has short-acting effects, unlike GTN.
GDN ¼ glyceryl dinitrate; GTN ¼ glyceryl trinitrate; IDP ¼ interventional diagnostic procedure.
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1852patients with high (>85%) pre-test probability of a
coronary artery stenosis support direct referral for
invasive coronary angiography with or without a
functional assessment with either a nonhyperemic
pressure ratio or fractional flow reserve (FFR) (9).
Noninvasive CTCA is associated with high sensi-
tivity for the detection of epicardial CAD. In the
United Kingdom, Clinical Guideline 95 of the Na-
tional Institute for Health and Care Excellence
recommends CTCA as the first-line diagnostic
technique for patients with anginal chest pain and
no history of CAD (31). Thus, an increasing pro-
portion of patients who undergo invasive coronary
angiography have not undergone functional stress
testing, meaning that information on ischemia is
often lacking at the time of anatomic testing with
either invasive or noninvasive angiography. This
gap presents new challenges for decision making in
patients with INOCA. Practice guidelines recom-
mend (Class I, Level of Evidence: A) the use of
invasive measures of coronary disease severity to
assess for flow-limiting coronary disease (32,33),
but many consensus guidelines do not emphasize
invasive testing of coronary vascular function in
patients with INOCA. This means that clinicians do
not assess for ischemia caused by disordersof coronary vasomotion, leading to diagnostic
uncertainty.
Looking forward, coronary microvascular dysfunc-
tion presents an unmet therapeutic need, and novel
therapies, including implantable devices, are being
actively pursued. Examples include the coronary si-
nus reducer stent for the treatment of refractory
angina (NCT02710435) and pressure-controlled inter-
mittent coronary sinus occlusion in acute MI
(NCT03625869). The main objective of coronary sinus
device therapy is to induce a controlled increase in
coronary sinus blood pressure, thereby increasing
retrograde myocardial perfusion to reduce the pro-
pensity to myocardial ischemia. Clinical evidence
from randomized controlled trials involving coronary
sinus device therapy is awaited with great interest.
PROGNOSIS. Patients with undiagnosed chest pain
(including those who have undergone cardiac in-
vestigations) are at increased risk for cardiovascular
events for at least 5 years (34). Women with angina
appear to be particularly burdened by symptoms and
morbidity even after reassuringly “normal” findings
on invasive coronary angiography (35).
There are evolving data from many large prospec-
tive studies on the independent prognostic impact of
FIGURE 2 Cardiac Catheterization Laboratory Interventional Diagnostic Procedure Protocol
Proposed step-by-step approach to guidewire-based assessment of coronary vascular function using thermodilution or Doppler and then
vasoreactivity testing using acetylcholine (Ach). This simple approach focuses on thermodilution, which is straightforward to include during
daily practice. Note that some operators may prefer to perform vasoreactivity testing first without the guidewire, allowing Ach challenge prior
to any short-acting nitrate administration. HMR ¼ hyperemia microvascular resistance; IC ¼ intracardiac; LVEDP ¼ left ventricular end-
diastolic pressure; LV gram ¼ left ventriculogram; NHPR ¼ nonhyperemic pressure ratio; seg ¼ segment; TT ¼ transit time (for bolus of
normal saline); other abbreviations as in Figure 1.
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FIGURE 3 Rising Trend in Citations in Human Coronary Vascular Physiology
A stacked area chart depicting the magnitude of change in citations between 1988 and 2018 and total values across this time period. Citations
of “coronary vascular dysfunction and human” (https://www.ncbi.nlm.nih.gov/pubmed/?term¼coronaryþvascularþdysfunctionþhuman;
search date February 2, 2020).
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1854coronary microvascular disease on major adverse
cardiovascular event(s) (MACE). Data from the Na-
tional Heart, Lung, and Blood Institute–sponsored
WISE (Women’s Ischemia Syndrome Evaluation)
study suggest that there is a worse prognosis in pa-
tients with INOCA: the 5-year annualized risk for
MACE was 16.0% in women with nonobstructive CAD,
7.9% in women with normal coronary arteries, and
2.4% in an asymptomatic control group (p # 0.002
after adjustment for baseline cardiovascular risk)
(36). After mean follow-up of 5.4 years, the time-to-
event analysis confirmed that low coronary flow
reserve (CFR) was a robust independent predictor of
MACE (hazard ratio: 1.20; 95% confidence interval
[CI]: 1.05 to 1.38; p ¼ 0.008). Similarly, a large Danish
cohort study of 11,223 patients found an increased
risk for MACE among patients with angina with
diffuse nonobstructive CAD and those with normal
coronary arteries (adjusted hazard ratios: 1.85 and
1.52, respectively), compared with a reference popu-
lation. Taqueti et al. (14) recently produced a pro-
vocative study showing that MACE risk in women is
driven by reduced CFR and not obstructive CAD, with
CFR an important predictor of events even in thosewithout obstructive CAD (adjusted hazard ratio: 1.69;
95% CI: 1.04 to 2.76; p ¼ 0.03) (14). The adverse
prognostic importance of impaired coronary vaso-
motion has also been identified in a meta-analysis of
6 studies including 1,192 subjects who experienced
243 cardiovascular events during a follow-up period
of 3.8 to 9.7 years. The overall relative risk was 2.38
(95% CI: 1.74 to 3.25), and the risk (2.49) was even
higher in 1,048 patients (n ¼ 209 events) who had
undergone acetylcholine reactivity testing (37).
TREATMENT. Historically, there was no randomized
evidence that a diagnostic strategy linked to therapy
improves patient well-being. The CorMicA (Coronary
Microvascular Angina) trial was undertaken to
address this evidence gap (11,38). Patients with
INOCA were randomized 1:1 to the intervention group
(stratified medical therapy, interventional or func-
tional diagnostic procedure disclosed) or the control
group (standard care, IDP performed, results not
disclosed). The diagnosis of a clinical endotype (MVA,
VSA, both, or none) was linked to guideline-based
management (10). After disclosure of the IDP result,
more than one-half of treating clinicians changed the
initial diagnosis and treatment on the basis of
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1855angiography alone. The intervention was associated
with a mean improvement of 11.7 units in the Seattle
Angina Questionnaire summary score [11] at 6 months
(95% CI: 5.0 to 18.4; p ¼ 0.001) (the primary endpoint)
associated with improvements in quality of life (EQ5D
index: 0.10 U; 95% CI: 0.01 to 0.18; p ¼ 0.024). Longer
term follow-up to 1 year has confirmed that these
benefits are maintained (39). In summary, the Cor-
MicA study provides clinical evidence of better qual-
ity of life for patients with angina without obstructive
CAD when management is guided by invasive tests of
coronary vascular function.
THERAPEUTIC NIHILISM AND SEX BIAS? Some cli-
nicians may take the view that patient benefits can be
achieved by assessing coronary function (40). A
simpler, pragmatic approach may be to administer a
trial of medical therapy as a matter of routine in all
symptomatic patients and assess their responses over
time, representing a trial of therapy. An angiography-
guided approach avoids prolonging the procedure
(about 15 min) and the cost (guidewire, adenosine,
and acetylcholine) of the IDP. We contend that ther-
apeutic nihilism is not in the best interest of patients
and that precision medicine (the right treatment for
the right patient at the right time) is preferred (25).
This may be especially relevant considering that
affected patients are often women (41). Practice
guidelines give clear treatment protocols for these
conditions (9), now supported by evidence from
randomized, controlled trials. Furthermore, avoiding
unnecessary medicines and optimizing therapy when
linked to the correct diagnosis will benefit patients,
health care providers, and the health care system (11).
CORONARY PHYSIOLOGY AND DIAGNOSIS OF
VASOMOTOR DISORDERS. Coronary vascular func-
tion reflects contributions from the epicardial conduit
coronary arteries, its intramyocardial branches, and
the microcirculation. The key functional parameters
are vascular tone, vasodilator reserve, and resistance.
Coronary resistance is determined mainly by intra-
mural arterioles <400 mm in diameter. CFR reflects
the vasodilator capacity of the coronary circulation.
CFR is a global measure of vasodilator capacity that
may be impaired by abnormalities of the conduit
coronary arteries, the microcirculation through to the
capillaries, or both compartments. CFR may also be
limited if basal flow is high, if diastolic time is
reduced, or if intramyocardial pressure is
increased (42).
PATHOPHYSIOLOGIC BASIS OF CORONARY
VASOMOTOR DISORDERS. A disorder of coronary
vascular function can be caused by structural and/or
functional abnormalities (3–5), and the vasodilatorresponse to hyperemic stimulants, such as pharmaco-
logical stress (43,44) or exercise (45), may be impaired.
Coronary microvascular dysfunction (increased resis-
tance) may result from remodeling of the vascular
wall, inflammation, alterations in the composition
and volume of the extravascular (interstitial) matrix
(46), and systemic changes including capillary
rarefaction (47) and arteriolar dysfunction (48–50).
Vascular function may vary among different coro-
nary artery territories, and normal global CFR may
mask impaired vasodilator reserve in a single major
artery (42). Regional differences and variations in
resting flow support the rationale for estimation of
coronary flow capacity by positron emission tomog-
raphy (49) and for assessing multiple coronary ar-
teries during invasive management, when clinically
appropriate.
Coronary artery spasm represents acute, flow-
limiting vasoconstriction (51). Kaski et al. (52)
showed that coronary hyperreactivity is responsible
mainly for focal rather than diffuse epicardial vaso-
spasm. Coronary artery spasm is caused by hyperre-
activity of vascular smooth muscle cells and a
triggering stimulus. The cause of vascular smooth
muscle cell hyperreactivity is incompletely under-
stood. Endothelial dysfunction is associated with
coronary artery spasm, enhancing its likelihood and
severity, but endothelial dysfunction is not the pri-
mary driver (51). Cardiovascular risk factors, inflam-
mation, oxidative stress, genetic factors, and ethnic
differences are implicated. Coronary artery imaging
using 18F-fluorodeoxyglucose positron emission to-
mography/computed tomography has identified
localized inflammation in the coronary adventitia and
perivascular adipose tissue of patients with VSA (53).
Rho-kinase mediates epicardial coronary spasm and
microvascular spasm, especially in patients with
microvascular dysfunction (54). Autonomic imbal-
ance, hyperventilation, and platelet activation are
potential triggers. Ethnic differences in coronary
spasm, such as in Japanese patients (53), reflect an
expansion of the personalized medicine concept.
Endothelial dysfunction typically precedes and
causes atherosclerosis. Endothelium-derived nitric
oxide mainly mediates vasodilatation of the conduit
epicardial coronary arteries, whereas endothelium-
derived hyperpolarizing factors–mediated responses
determine endothelium-dependent vasodilatation of
resistance arteries (e.g., coronary microvessels) (55).
Endothelial dysfunction is associated with vascular
risk factors, including diabetes mellitus and circu-
lating inhibitors of nitric oxide synthase, as reflected
by serum concentrations of asymmetrical dimethy-
larginine (13,56), and low endothelial shear stress
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(e.g., redox imbalance) is distinct from vasospasm
(rho-kinase-induced myosin light chain phosphory-
lation) (55). Coronary endothelial dysfunction is
therapeutic target for lifestyle and pharmacological
interventions, notably statins and angiotensin-
converting enzyme inhibitors.
Endothelial function of the coronary artery may be
defined according to the method used. If assessed
using coronary angiography, endothelial dysfunction
is defined as a decrease in 1 or more segments of an
epicardial coronary artery luminal diameter of >20%
after intracoronary infusion of low doses of acetyl-
choline (58). Normal endothelial function may be
defined as normal (%D coronary artery diameter
[acetylcholine] >20%), mild endothelial dysfunction
(%D diameter [acetylcholine] 20% to 20%), or severe
endothelial dysfunction (%D coronary diameter
[acetylcholine] <20%) (59). Endothelium-
dependent epicardial vasomotion can also be
assessed by calculating the percentage in coronary
cross-sectional area change in response to intra-
coronary acetylcholine (change in epicardial cross-
sectional area >0% is considered normal) (16).
Endothelial dysfunction may also be described
according to changes in coronary blood flow (CBF) in
response to infusion of acetylcholine (16,59). Normal
coronary endothelium-dependent function is defined
as a Doppler-derived increase in CBF of $50% (i.e., a
ratio of >1.5 in response to acetylcholine, calculated
by dividing CBF after 104 mol/l acetylcholine
[18.2 mg/ml] by the baseline). Endothelial dysfunction
can be further classified as mild (0% to <50% change
in CBF) or severe (<0% change in CBF). Impaired
coronary endothelium-independent function can be
defined as a ratio of flow velocity to adenosine, with
cutoffs varying from #2.0 to 2.5 (16,60).
Coronary endothelial dysfunction revealed by
acetylcholine reactivity testing in the catheterization
laboratory is associated with inducible myocardial
ischemia determined by injection of 99mTc sestamibi
and single-photon emission computed tomography
(61). In a study of 299 patients undergoing coronary
angiography and endothelial function testing, 60 had
normal endothelial function and 239 had abnormal
endothelial function. When stratifying patients by the
presence or absence of endothelial dysfunction, in
those with preserved endothelial function, troponin I
concentrations were higher in patients who devel-
oped MACE during 7.0  0.3 years of follow-up
compared with those who did not (1.35 ng/l [inter-
quartile range: 1.1 to 2.1 ng/l] vs. 0.7 ng/l [inter-
quartile range: 0.7 to 1.1 ng/l]; p ¼ 0.02) (62). These
findings are important because coronary endothelialdysfunction is a modifiable, therapeutic target for
life-style interventions and medical therapy (statins,
angiotensin-converting enzyme inhibitors), and a
clinical strategy based on endothelial function testing
may improve quality of life (22). Two trials of
endothelin-1 receptor antagonists in patients with
MVA reported favorable results (63,64). The potential
for patient benefits with endothelin receptor antag-
onist therapy is currently being evaluated in a preci-
sion medicine trial of zibotentan in MVA
(NCT04097314 and ACTRN12618000021279).
HOW TO ASSESS CORONARY VASCULAR
DYSFUNCTION IN THE
CATHETERIZATION LABORATORY?
SETUP. The purpose of this section is to give practical
guidance to clinicians on how to assess coronary
vascular function in the catheterization laboratory
(Table 2) (65,66). A step-by-step guide is illustrated in
Figure 2. Vasoactive medications should be withheld
for at least 24 h. Coronary vascular function can be
assessed by a trained cardiologist using invasive
techniques. Radial artery access generally works well.
A cocktail of intra-arterial vasodilator drugs to pre-
vent radial artery spasm may confound subsequent
measurements of coronary function. We generally
avoid the use of intra-arterial calcium channel an-
tagonists and longer acting nitrates (e.g., verapamil
and isosorbide dinitrate). Glyceryl trinitrate has a
short half-life and is preferred. Standard coronary
catheters can be used, although the benefits of a
smaller arteriotomy and guide catheters (5-F) include
reduced radial spasm and reduced risk for
vascular injury.
CORONARY ANGIOGRAPHY. The cardiologist visu-
ally assesses antegrade flow of contrast media during
cine angiography. Semiquantitative analysis may be
undertaken by calculating the TIMI (Thrombolysis In
Myocardial Infarction) frame count (49). In patients
with unobstructed epicardial coronary arteries, a
corrected TIMI frame count >27 (images acquired at
30 frames/s) suggests MVA due to impaired resting
flow (coronary slow-flow phenomenon) (67). Slow
flow points to an increase in vascular resistance under
resting conditions and is typically seen in male
smokers and may be implicated in propensity to acute
coronary syndromes (68).
We typically use a diagnostic JR4 (Judkins right)
catheter to perform angiography of the right coronary
artery before crossing the aortic valve to measure left
ventricular end-diastolic pressure (LVEDP). Elevated
LVEDP may reflect heart failure, which is associated
with CMD (69). We then use a left coronary guiding
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1857catheter with reasonable support (e.g., EBU3.5, extra
backup), which permits reproducible transit time in-
jections and good intubation of the left main coronary
artery for acetylcholine infusions. In choosing a
guiding catheter, we exercise caution to ensure co-
axial coronary intubation and avoidance of pressure
damping to avoid injury of the vascular wall.
INTERVENTIONAL DIAGNOSTIC PROCEDURE (IDP).
The IDP is a combinatory technique involving direct
invasive measurements of coronary vascular function
initially with a diagnostic guidewire, then acetylcho-
line reactivity testing (Tables 1 and 2, Figure 1). As a
practical guide, following acquisition of the coronary
angiogram, we recommend that the IDP initially focus
on the use of a diagnostic guidewire and then, as
appropriate and feasible, acetylcholine vasoreactivity
testing. There is no firm consensus on the approach
(9,60). We advocate this diagnostic sequence
because, should vasospasm occur following intra-
coronary infusion of acetylcholine, the assessment of
resting physiology becomes confounded by elevated
sympathetic drive. An alternative approach sees
vasospasm provocation first, before assessment of
CFR. This approach is advocated by some who have
concerns about coronary vasospasm testing if a short-
acting nitrate is initially administered (e.g., to pre-
vent vasospasm if using radial artery access or to
optimize coronary angiography). In the authors’
experience, epicardial coronary spasm is still readily
provoked despite nitrate administration during
transradial access for angiography.
DIAGNOSTIC GUIDEWIRE. The guidewire procedure
is performed as an adjunct to coronary angiography.
The IDP should be focused to a single major coronary
artery to limit the duration of the procedure. Addi-
tional studies in a second coronary artery may be
appropriate if the initial test results are negative and
clinical suspicion is high.
The left anterior descending coronary artery is
usually preferred as the pre-specified target vessel,
reflecting its subtendedmyocardial mass and coronary
dominance (Table 2), and this artery is in our experi-
ence typically reactive to the effects of acetylcholine. If
technical factors, such as tortuous coronary anatomy,
preclude instrumentation of this artery, then the
circumflex or right coronary artery should be assessed.
Intravenous heparin (50 to 70 U/kg) should be
administered to achieve therapeutic anticoagulation
(activated clotting time w250 s) before coronary
instrumentation. Diagnostic options include coronary
thermodilution using a pressure-temperature sensor
guidewire (PressureWire X, Abbott Vascular, Santa
Clara, California) or a Doppler technique (ComboWireXT or Flowire, Philips Volcano Corporation, San Diego,
California). The ComboWire XT connects to the Com-
boMap system (Philips Medical Systems, Eindhoven,
the Netherlands).
Typically, intra-arterial glyceryl trinitrate is given
routinely during coronary angiography, although we
suggest using 200 mg or less. The half-life of glyceryl
trinitrate is about 2 min, and thus after 10 min, only
3% of the medication is active, so it is therefore un-
likely to suppress a false-positive result for epicardial
vasospasm (70). The usual approach to inducing
steady-state hyperemia is by use of intravenous
adenosine (140 mg/kg/min) administered through a
large peripheral vein. Intravenous adenosine acti-
vates vascular A2 receptors, leading to predominantly
non-endothelium-dependent vasodilation, although
there may also be a lesser component of endothelial-
dependent vasodilation (71). Intracoronary bolus in-
jection of adenosine (up to 200 mg) or
nicorandil (2 mg) is an alternative option to assess
endothelium-independent vasodilatation (40). The
adenosine infusion is given for 2 to 3 min, and
although mild symptoms are common, it is generally
well tolerated. Hemodynamic markers of coronary
hyperemia are: 1) “ventricularization” of the distal
pressure waveform; 2) disappearance of distal
dicrotic pressure notch; and 3) separation of mean
aortic and distal pressures (72). Changes in heart rate,
blood pressure, and rate-pressure product are less
reliable measures of coronary hyperemia (73).
CORONARY THERMODILUTION. The principle of
coronary thermodilution is that transit time, derived
from a bolus intracoronary injectate of normal saline
administered at room temperature to mix with blood
at body temperature, represents the inverse of CBF
(74). From a practical perspective, the diagnostic
guidewire connects wirelessly to transmit data to a
personal computer using dedicated analysis software
(Coroventis, Uppsala, Sweden). The guidewire sensor
tip is positioned at the tip of the guiding catheter, and
the pressure measurement from the wire is equalized
with that of the guiding catheter. The guiding cath-
eter should be coaxial with the long axis of the cor-
onary artery to ensure effective delivery and mixing
of saline. The sensor is then positioned in the distal
third of the coronary artery followed by 3 intra-
coronary injections of saline (3 ml) at room tempera-
ture. The mean transit time is measured with each
bolus and averaged to calculate the resting mean
transit time. When steady-state hyperemia is ach-
ieved by pharmacological stress testing, 3 additional
injections of 3 ml of room-temperature saline are
performed. The transit time is automatically
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calculate the hyperemic mean transit time. Simulta-
neous measurements of mean aortic pressure (by
guiding catheter) and mean distal coronary pressure
(by pressure wire) are also made during
maximal hyperemia.
CFR is calculated using thermodilution as resting
mean transit time divided by hyperemic mean transit
time (abnormal CFR is defined as #2.0) (60,75). The
index of microvascular resistance (IMR) is calculated
as the product of distal coronary pressure at maximal
hyperemia multiplied by the hyperemic mean transit
time (76). IMR has a weak correlation with the sub-
tended myocardial mass, leading some to propose
vessel-specific cutoffs. A guiding catheter must also
be intubated well within the left main coronary artery
to ensure reproducible coronary transit time esti-
mates. The normal values for IMR and CFR have been
challenging to define. The normal range of IMR is
considered to be <25, on the basis of 3 studies eval-
uating IMR in different populations (77–80). The only
truly “healthy” population used to validate IMR was
20 subjects who underwent IMR testing prior to
ablation for supraventricular rhythm disturbance. In
this study, Solberg et al. (80) noted the upper limit of
the estimated 95th percentile for IMR in 20 healthy
control subjects to be 27 (95% CI: 21 to 34). The in-
vestigators stated that if a larger cohort of control
subjects were used, this upper limit would likely be
reduced. More recently, IMR $18 was identified as the
optimal cutoff for the prediction of MACE in an Asian
population of subjects with INOCA (54).
Flow-limiting coronary disease may be calculated
during the same setting of adenosine-induced hy-
peremia simultaneously from the ratio of mean distal
coronary pressure to mean aortic pressure at maximal
hyperemia; abnormal FFR is defined as #0.80 (33) or
a nonhyperemic pressure ratio (81). We advocate a
patient-centered approach to decision making. The
binary thresholds of continuous data should be
viewed within the context of the patient. A CFR be-
tween 2.0 and 2.5 reflects an impaired vasodilator
reserve and may be considered a CFR “gray zone,” as
is also the case for FFR (0.75 to 0.82). CFR, IMR,
nonhyperemic pressure ratio, and FFR have prog-
nostic significance across the diagnostic range of their
values. An accepted caveat of CFR measured by any
modality is its inherent variability related to influ-
ence of resting hemodynamic status. CFR is also
affected by epicardial CAD and so is not specific to
microcirculatory pathology.
PRESSURE AND FLOW MEASUREMENTS. The rela-
tive simplicity and accessibility of thermodilution-derived CFR and IMR are attractive, but there are
inherent limitations. The setup conditions should be
constant during the thermodilution measurements.
Specifically, the guide catheter should be engaged
without pressure damping, and the position of the
guidewire sensor should be constant to reduce vari-
ability in the saline transit times. Coronary vascular
function can be assessed using a pressure-flow wire
(ComboWire XT) or a Doppler wire to measure coro-
nary flow velocity (Flowire) (66). CFR assessed using
thermodilution (82) slightly overestimates flow
reserve at higher levels compared with CFR assessed
using Doppler. Doppler-derived hyperemic micro-
vascular resistance may be a closer correlate of
microvascular function assessed noninvasively using
cardiac magnetic resonance (myocardial perfusion
reserve) (83). Simultaneous measurement of coronary
flow velocity reserve with pressure enables myocar-
dial resistance (hyperemic microvascular resistance)
to be calculated (84).
Selective intracoronary infusion of acetylcholine
using a dedicated microcatheter may be preferred
rather than infusing the acetylcholine through a
guiding catheter (66). The advantage of using a
microcatheter is the subselective infusion of acetyl-
choline and, potentially, avoidance of pancoronary
vasospasm. The disadvantage of this approach is the
additional coronary instrumentation, related risks for
vascular injury, and expense. We think there are pros
and cons to using a microcatheter. In the end, oper-
ator preference and the diagnostic circumstances of
the procedure should guide the approach on an in-
dividual patient basis.
A Doppler wire may be used to measure coronary
flow velocity during intracoronary infusion of
acetylcholine (22). When using Doppler, the infusion
catheter is placed in the proximal segment of the
target artery, and the Doppler wire is sited in the mid
to distal segment. Because the Doppler wire is less
flexible than a standard coronary guidewire, a “buddy
wire” or a microcatheter may be needed to safely
advance the Doppler wire into the target artery. Cor-
onary angiography is acquired to estimate the diam-
eter of the coronary artery at baseline and after each
infusion of acetylcholine. A projection without fore-
shortening is essential.
PHARMACOLOGICAL CORONARY REACTIVITY
TESTING IN THE CATHETERIZATION LABORATORY.
Coronary vascular function is assessed by infusion of a
vasoactive substance such as acetylcholine, substance
P, or ergonovine (65). The physiological alterations to
vascular tone following intracoronary infusion of
these substances are determined by the relative
TABLE 3 Indications for Measuring Coronary Vascular Function as an Adjunct to Clinically Indicated Coronary Angiography
Condition Invasive Diagnostic Management Abbreviation
Current indications
Angina No obstructive coronary disease INOCA
Myocardial infarction Infarction without culprit stenosis for which vasospastic angina is considered MINOCA
Cardiac arrest In certain scenarios (ventricular arrhythmias, resuscitated cardiac arrest) for which no clear
cardiac cause can be found and the patient is stabilized with normal LV function, no
obstructive CAD, and normal ECG findings
VSA
Future possibilities
Angina Suspected obstructive CAD Pre-PCI
Post-PCI Post-PCI
Heart failure Preserved systolic function HFpEF
After cardiac transplantation
Myocardial infarction Stratification of risk and prognosis STEMI, NSTEMI
No obstructive coronary disease MINOCA
CAD ¼ coronary artery disease; ECG ¼ electrocardiographic; HFpEF ¼ heart failure with preserved ejection fraction; INOCA ¼ ischemia with no obstructive coronary artery
disease; LV ¼ left ventricular; MINOCA ¼ myocardial infarction with no obstructive coronary disease; NSTEMI ¼ non–ST-segment elevation myocardial infarction;
PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction; VSA ¼ vasospastic angina.
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1859functions of the endothelium and smooth muscle cells
(85). Vasodilatation reflects a dominant response
mediated by endothelial cells (vascular health) over
the constrictor effects of vascular smoothmuscle cells,
whereas vasoconstriction reflects a dominant smooth
muscle cell effect over impaired endothelial cell–
mediated vasorelaxation (vascular dysfunction).
The most established approach for vasoreactivity
testing is by intracoronary infusion of acetylcholine
(60). We support a pragmatic approach for coronary
reactivity testing according to whichever protocol
might work at individual centers. A standard
approach involves sequential infusion of acetylcho-
line at concentrations approximating 0.182, 1.82, and
18.2 mg/ml (106, 105, and 104 mol/l, respectively)
at 1 ml/min for 2 min using a mechanical pump.
These doses were historically derived using experi-
ments adopting subselective infusion through an
intracoronary catheter into the left anterior
descending coronary artery, assuming a resting flow
rate of 80 ml/min. The effective concentration of
acetylcholine at the tissue level was estimated at
108 to 106 M. Alternative options to facilitate ease
of adoption include manual infusion of 2, 20, 100,
and 200 mg (86). Susceptibility to coronary vaso-
spasm is assessed by manual infusion of 100 mg
(5.5 ml 104 M) or 200 mg (11 ml 104 M) over 20 s
into the left main coronary artery (87). On a case-by-
case basis, a dose of 200 mg may be infused to
enhance sensitivity without adversely affecting
specificity (86,88).
When microvascular spasm occurs, coronary flow
transiently reduces or ceases in the absence ofepicardial coronary artery spasm; that is, the diam-
eter of the coronary diameter is maintained in asso-
ciation with transient reduction of flow (TIMI flow
grade #2), while the patient generally experiences
chest pain in association with ischemic changes on
electrocardiography. Prompt recovery is typical, and
nitrates can be administered if necessary. Epicardial
coronary spasm is defined according to the COVADIS
(Coronary Vasomotion Disorders International Study)
criteria requiring reproduction of chest pain and
ischemic electrocardiographic changes in association
with $90% vasoconstriction (89). In the case of se-
vere epicardial spasm, it may not be possible to
determine whether microvascular spasm coexists.
Reflecting the role of the right coronary artery to
supply the sinus and atrioventricular nodes (or
circumflex in left-dominant anatomy), transient
bradycardia commonly occurs. Given the propensity
of acetylcholine to induce bradycardia, safety is
ensured by administering a half dose (i.e., 50 mg
instead of 100 mg). Historically, a temporary
implantable transvenous pacing line was used to
balance this risk, but this procedure is not without
risk and, in our view, is not routinely needed, unless
the right coronary artery is infused. We advocate
proceeding without transvenous pacing and applying
caution with testing the right coronary or left-
dominant circulations. Self-limiting atrial fibrillation
is also common (8%), particularly during evaluation
of right coronary vascular function (90). Patients
undergoing clinically indicated coronary angiography
typically have risk factors for cardiovascular disease,
including atrial fibrillation.
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1860Ergonovine may induce coronary vasospasm via
serotonin 1D receptors on vascular smooth muscle
cells. Intracoronary ergonovine (20 to 60 mg) is an
alternative to acetylcholine for the assessment of
coronary vasospasm in some Asian countries (91).
Acetylcholine is useful for assessing macrovascular
and microvascular function, is safer, and is more
widely available.
INTRAMYOCARDIAL CORONARY COURSE: INVASIVE
PHARMACOLOGICALASSESSMENT. Myocardial bridging
is also prevalent in INOCA, probably because of
endothelial dysfunction within and distal to affected
segments (92). Coronary reactivity testing in patients
using a myocardial bridge (MB) may provoke tran-
sient spasm and chest pain that reproduces their
symptoms. Furthermore, the ischemia-generating
potential of MBs may have contributions from dy-
namic epicardial coronary obstruction. Despite a
predominantly systolic effect of MBs, it has been
demonstrated that MBs also affect diastolic flow,
particularly under enhanced inotropism and tachy-
cardia, both occurring during physical exercise.
Inotropic challenge with pressure guidewire interro-
gation during dobutamine in addition to acetylcho-
line has diagnostic value in such patients (93).
NONPHARMACOLOGICAL APPROACHES TO STRESS
TESTING IN THE CATHETERIZATION LABORATORY.
Atrial pacing has been used to increase CBF and shear
stress in assessing vasoactive responses (94). How-
ever, this approach limited because the achievable
maximal tachycardia is limited by Wenckebach block,
thus affecting CFR determination. Supine exercise
testing during coronary angiography with radial or
brachial artery access is feasible and can provide
clinically relevant information on disease mecha-
nisms (95). Rahman et al. (95) measured coronary
flow velocity and pressure under resting conditions,
during intravenous adenosine–mediated hyperemia
(140 mg/kg/min), and during bicycle exercise using a
supine ergometer in the catheterization laboratory.
They found that in patients with angina without
obstructive CAD (n ¼ 85), CFR but not microvascular
resistance identified patients with maladaptive
physiological responses to exercise and sub-
endocardial myocardial ischemia (n ¼ 55; hyperemic
subendocardial/subepicardial perfusion ratio <1.0, as
revealed by stress perfusion cardiovascular magnetic
resonance). This finding ties in with the idea of CFR
as an invasive functional correlate of impairments in
exercise capacity and myocardial perfusion and lends
support to the role of exercise testing in the cathe-
terization laboratory.PROCEDURAL SAFETY. The risks of an IDP are those
of coronary instrumentation with a guidewire and
adverse physiological reactions. In CorMicA, IDPs
were feasible with diagnostic information achieved in
99% of the study population. No serious adverse
events occurred. Considering adverse effects of cor-
onary reactivity testing, atrial fibrillation occurred in
1 in 20 patients. This was self-limiting in all but 1
patient, in whom chemical cardioversion was ach-
ieved with intravenous amiodarone. Transient bra-
dycardias reflect expected physiological responses,
which will resolve immediately after discontinuation
of the acetylcholine infusion. A coughing maneuver
may be helpful, and vasospasm is typically transient.
The cardiac catheterization laboratory environment
facilitates patient safety. Multiple publications sup-
port the safety of coronary reactivity testing when
administered in trained hands (44).
Coronary injury may occur secondary to the guid-
ing catheter or diagnostic guidewire, typically at the
start of the standard care procedure. These compli-
cations are more likely to occur at the start of the
procedure in the hands of an inexperienced trainee
when the guiding catheter is less compliant. Rarely, a
dissection may be secondary to the diagnostic
guidewire. For these reasons, the IDP should be per-
formed by an experienced interventional cardiologist
or by a trainee under direct supervision. Coronary
dissections are not a consequence of the effects of
acetylcholine.
COMPLEMENTARY MEASUREMENTS. LVEDP is a
clinically relevant parameter that is straightforward
to measure and provides information on fluid balance
and left ventricular (LV) pump function. A low LVEDP
(i.e., <3 mm Hg) points to dehydration. Increased
LVEDP may reflect volume overload (normal
pressure-volume relationship), abnormal LV filling or
compliance (diastolic dysfunction), abnormality of LV
contractility (systolic dysfunction), or a combination
of these factors. We recommend that LVEDP be
measured routinely during invasive diagnostic pro-
cedures. An indwelling LV catheter may also measure
alterations in LVEDP during infusion of acetylcholine.
When prior information on LV function is not already
available, ventriculography should be considered.
Furthermore, depending on the results of left heart
catheterization, occasionally, ad hoc right heart
catheterization may be appropriate (e.g., to assess for
intracardiac shunts, pulmonary hypertension, or as
an alternative cause of exercise impairment). Nonin-
vasive imaging using echocardiography and cardio-
vascular magnetic resonance imaging provides
complementary diagnostic information, notably on
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valve function, and pulmonary artery systolic
pressure.
WHEN TO MEASURE CORONARY
VASCULAR FUNCTION
There is a growing body of research underpinning the
rationale for clinical tests of coronary vascular func-
tion (Figure 3). The clinical indication during coronary
angiography should be personalized and considered
on a case-by-case basis. A benefit/risk ratio applies.
Benefits to patients, health care providers, and in-
surers relate to making the correct diagnosis with
linked therapy (personalized medicine) and avoid-
ance of inappropriate treatments and/or downstream
investigations. An adjunctive IDP carries theoretical
risks and prolongs the duration of the procedure,
usually by 10 to 30 min. Staff training and experience
can help optimize patient flow through the catheter-
ization laboratory.
INDICATIONS. The suggested clinical indications for
an IDP are listed in Table 3. The indications align with
the classification of MVA by Camici and Crea (96). In
patients with stable symptoms, CorMicA provides
proof-of-concept evidence that stratified therapy
guided by results from an adjunctive IDP may be
beneficial to patients with INOCA. Larger scale
studies will be needed to substantiate new practice
guideline recommendations. Pharmacological and
nonpharmacological measures together bring patient
benefits (97).
Coronary vascular dysfunction is implicated in the
pathogenesis of several forms of cardiac disease,
notably stable ischemic heart disease, acute MI, hy-
pertension, diabetes, nonischemic cardiomyopa-
thies, and heart failure with preserved ejection
fraction. In patients with acute ST-segment eleva-
tion MI, multiple studies provide evidence support-
ing the prognostic value of IMR and CFR when
measured at the end of percutaneous coronary
intervention, and clinical trials of stratified medicine
on the basis of IMR are ongoing (98). There is some
evidence that coronary vascular dysfunction is
implicated in the pathophysiology of MINOCA (99).
More research on how vascular function testing may
associate with treatment response within endotypes
of INOCA and MINOCA is needed. Recent evidence
supports a plausible role for targeted therapy
(endothelin receptor A antagonists) modulating the
endothelin-1 system in coronary microvascular
dysfunction (100).In heart failure with preserved ejection fraction,
coronary microvascular dysfunction is implicated
(69), notably in patients with cardiovascular risk
factors such as hypertension. Presently, there are no
evidence-based treatments for heart failure with
preserved ejection fraction, but coronary microvas-
cular dysfunction could become a treatment target.
Coronary microvascular dysfunction is also impli-
cated in cardiac transplant vasculopathy, and
angiotensin-converting enzyme inhibitors may be
beneficial (101).CONCLUSIONS AND FUTURE DIRECTIONS
Contemporary practice guidelines state that in
patients with anginal symptoms and no obstructive
coronary arteries, guidewire-based CFR and/or
microcirculatory resistance measurements should be
considered (Class IIa), and pharmacological tests
may be considered (Class IIb) (9). In this review, we
described the available techniques, practical consid-
erations, and relevant clinical scenarios in which an
IDP may be useful. Adopting an IDP empowers car-
diologists allowing personalized medicine for indi-
vidual patients. Stratifying undifferentiated patients
in the clinic will pave the way for new insights into
vascular mechanisms and disease-modifying therapy.
Diagnostic advances are emerging, notably mea-
surement of absolute myocardial resistance (102). The
Achilles’ heel of anatomic imaging with CTCA is the
lack of information on vasomotor function. The
extent and clinical significance of false-negative re-
sults in patients with angina and no obstructive CAD
is currently being investigated (CorCTCA [Coronary
Microvascular Function and CT Coronary Angiog-
raphy]; NCT03477890) (103). Technological advances
are needed, and noninvasive coronary microvascular
disease strategies (e.g., positron emission tomogra-
phy, cardiovascular magnetic resonance) are
emerging. Developing evidence-based, disease-
modifying therapy is a priority (54). To that end,
randomized controlled trials of novel and repurposed
drugs, as well as precision medicine, hold future
promise.
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